ICCC News and Press, ImmuCell Corporation From 06/15/23

PORTLAND, Maine, June 15, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health a...

2023-05-12 10:00:10 ET ImmuCell Corporation (ICCC) Q1 2023 Earnings Conference Call May 12, 2023 09:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Presentation Operat...

2023-05-11 16:29:08 ET ImmuCell press release ( NASDAQ: ICCC ): Q1 GAAP EPS of -$0.30. Revenue of $2.6M (-56.7% Y/Y). For further details see: ImmuCell GAAP EPS of -$0.30, revenue of $2.6M

PORTLAND, Maine, May 11, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health an...

PORTLAND, Maine, May 04, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health an...

PORTLAND, Maine, April 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health ...

ImmuCell Corporation (ICCC) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Presentation Operator Good morning, an...

The following slide deck was published by ImmuCell Corporation in conjunction with their 2022 Q4 earnings call. For further details see: ImmuCell Corporation 2022 Q4 - Results - Earnings Call Presentation

ImmuCell press release ( NASDAQ: ICCC ): FY GAAP EPS of -$0.32. Revenue of $18.57M (-3.5% Y/Y). EBITDA (a non-GAAP financial measure described on page 5 of this press release) decreased to approximately $350,000 during the year ended December 31, 2022 from $2,706,000 during th...

PORTLAND, Maine, Feb. 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health a...